

Supplemental file 3. Description of patients reported for anaphylaxis following immunization

ID	Brighton Collaboration level of diagnostic certainty^a	Vaccine(s) administered at initial AEFI.	Sex/Age at immunization (in years)	Delay of onset following immunization	Treatment	Medical assessment	Skin test results	Reimmunization
1	Level 1	MMRV, MenC-C, PCV	M/1,1	5 min	Adrenaline	Yes	Negative	Not reimmunized (antibody serology positive)
2	Level 1	dTaP-IPV	F/5,8	10min	Adrenaline, antihistamine, bronchodilator	Yes	Positive	Not reimmunized
3	Level 1	HepAB	F/41,5	Not reported	Adrenaline, antihistamine	No	NA	Not reimmunized
4	Level 2	HPV	F/14,2	40 min	Adrenaline, corticosteroids, bronchodilator	Yes	Negative	Reimmunized with HPV
5	Level 2	MMRV, Men C-C	F/1,0	25min	Antihistamines, corticosteroids	Yes	Negative	Reimmunized with MMR
6	Level 2	DTaP-HepB-IPV-Hib, PCV, Rotavirus	F/0,2	3min	Adrenaline	Yes	Negative	Reimmunized with DTaP-HepB-IPV-Hib, PCV, Rotavirus
7	Level 2	DTaP- IPV, PCV	M/4,6	10min	Adrenaline	Yes	Positive	Not reimmunized
8	Level 2	HPV	F/14,9	1h	None	No	NA	Not reimmunized (Awaiting evaluation by the allergist)
9	Level 2	HPV	F/14,8	10 min	Adrenaline, antihistamines, corticosteroid	No	NA	Not reimmunized

Supplemental file 3. Description of patients reported for anaphylaxis following immunization (continued)

ID	Brighton Collaboration level of diagnostic certainty^a	Vaccine(s) administered at initial AEFI.	Sex/Age at immunization (in years)	Delay of onset following immunization	Treatment	Medical assessment	Skin test results	Reimmunization
10	Level 2	HPV	F/22,5	20min	Antihistamines, Oxygen	No	NA	Not reimmunized (Awaiting evaluation by the allergist)
11	Level 2	HPV, MenC-C, PPSV23,	F/12,7	10min	Adrenaline, antihistamine, corticosteroid, bronchodilator	No	NA	Not reimmunized
12	Level 3	HPV	F/15,0	26h	No treatment administered	Yes	Negative	Reimmunized with HPV
13	Level 3	DTaP-IPV-Hib	F/0,5	3min	Adrenaline, antihistamine, corticosteroid	Yes	No skin test performed	Reimmunized with DTaP-HepB-IPV-Hib, MMR
14	Level 3	HPV	F/15,1	Not reported	Adrenaline, antihistamine, Oxygen	Yes	No skin test performed	Reimmunized with HPV
15	Level 3	HPV	F/14,1	Not reported	Adrenaline, antihistamine, corticosteroid	Yes	No skin test performed	Reimmunized with HPV
16	Level 3	HPV	F/14,5	5 min	Adrenaline	No	NA	Not reimmunized (Patient's refusal)

Supplemental file 3. Description of patients reported for anaphylaxis following immunization (continued)

ID	Brighton Collaboration level of diagnostic certainty^a	Vaccine(s) administered at initial AEFI.	Sex/Age at immunization (in years)	Delay of onset following immunization	Treatment	Medical assessment	Skin test results	Reimmunization
17	Level 3	HepB	F/57,6	10min	None	No	NA	Not reimmunized (Awaiting evaluation by the allergist)
18	Signs and symptoms not reported	DTaP-IPV-Hib, PCV, Rotavirus	F/0,2	Not reported	Not reported	Yes	Negative	Reimmunized with DTaP-IPV-Hib, PCV, Rotavirus

^a Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007 Aug 1;25(31):5675–84.

DTaP-HepB-IPV-Hib: Diphtheria-tetanus-acellular-pertussis-HepatitisB-poliomyelitis-Haemophilus influenza type b vaccine, **DTaP-IPV-Hib:** Diphtheria-tetanus-acellular-pertussis-poliomyelitis-Haemophilus influenza type b vaccine, **HepB:** Hepatitis B vaccine, **Hep AB:** Hepatitis A and B vaccine, **HPV:** Human papilloma virus, **MenC-C:** Conjugated meningococcal serogroup C vaccine, **MMR:** measles-mumps-rubella vaccine, **MMRV:** measles-mumps-rubella-varicella vaccine, **PCV:** pneumococcal conjugated vaccine, **PPSV23:** 23 valent pneumococcal polysaccharidic vaccine